Sanofi SA
SNY
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
Can you achieve global diversification with multinational companies?
A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,683.90 | 11.50 | 0.13% |
| CAC 40 | 7,839.19 | 66.74 | 0.86% |
| DAX 40 | 22,744.81 | 181.93 | 0.81% |
| Dow JONES (US) | 45,800.96 | 584.82 | 1.29% |
| FTSE 100 | 10,208.07 | 80.11 | 0.79% |
| HKSE | 24,788.14 | 37.35 | 0.15% |
| NASDAQ | 21,220.61 | 425.97 | 2.05% |
| Nikkei 225 | 51,063.72 | 822.13 | -1.58% |
| NZX 50 Index | 12,912.11 | 163.19 | 1.28% |
| S&P 500 | 6,443.71 | 99.99 | 1.58% |
| S&P/ASX 200 | 8,481.80 | 4.60 | 0.05% |
| SSE Composite Index | 3,891.86 | 31.43 | -0.80% |